What common biomarkers characterize a triple-negative profile in breast cancer?

Pathologie Biologie

Volumn 63, Issue 4-5, 2015, Pages 224-229

  Kallel, I ^a,b   Rebai M ^a   Khabir, A ^b   Rebai A ^a  

^a UNIVERSITY OF SFAX   (Tunisia)

^b HABIB BOURGUIBA HOSPITAL   (Tunisia)

Author keywords

Biomarkers; Breast cancer; Prognosis; Triple negative profile

Indexed keywords

ANDROGEN RECEPTOR; BECLIN 1; BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; CD24 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 5; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HERMES ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; PROTEIN P62; PROTEIN P63; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; CD44 PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; TP53 PROTEIN, HUMAN; TUMOR MARKER; TUMOR PROTEIN;

BASAL LIKE BREAST CANCER; CANCER GRADING; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; DISEASE ASSOCIATION; ETHNICITY; GENE MUTATION; GENE OVEREXPRESSION; HIGH RISK POPULATION; HUMAN; NONHUMAN; ONCOGENE; PHENOTYPE; PREVALENCE; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CHEMISTRY; CLASSIFICATION; ETHNIC GROUP; ETHNOLOGY; FEMALE; MOLECULARLY TARGETED THERAPY; PROTO ONCOGENE; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; TRIPLE NEGATIVE BREAST NEOPLASMS;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRCA1 PROTEIN; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CYCLIN-DEPENDENT KINASE INHIBITOR P16; ETHNIC GROUPS; FEMALE; GENES, BRCA1; GENES, ERBB-1; GENES, P53; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANDROGEN; SENSITIVITY AND SPECIFICITY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84941808527     PISSN: 03698114     EISSN: 17683114     Source Type: Journal    
DOI: 10.1016/j.patbio.2015.07.005     Document Type: Review

References (100)

1. Kothari R., Morrison C., Richardson D., Seward S., O'Malley D., Copeland L., et al. The prognostic significance of the triple-negative phenotype in endometrial cancer. Gynecol Oncol 2010, 118:172-175.
2. Reis-Filho J.S., Tutt A.N. Triple-negative tumours: a critical review. Histopathology 2008, 52:108-118.
3. Oakman C., Moretti E., Galardi F., Biagioni C., Santarpia L., Biganzoli L., et al. Adjuvant systemic treatment for individual patients with triple-negative breast cancer. Breast 2011, 20(Suppl. 3):S135-S141.
4. Lin N.U., Vanderplas A., Hughes M.E., Theriault R.L., Edge S.B., Wong Y.N., et al. Clinicopathological features and sites of recurrence according to breast cancer subtype in the National Comprehensive Cancer Network (NCCN). J Clin Oncol 2012, 118(22):5463-5472. 10.1002/cncr.27581.
5. Thike A.A., Iqbal J., Cheok P.Y., Chong A.P., Tse G.M., Tan B., et al. Triple-negative breast cancer: outcome correlation with immunohistochemical detection of basal markers. Am J Surg Pathol 2010, 34(7):956-964.
6. Rakha E.A., Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol) 2011, 23:587-600.
7. Abd El-Rehim D.M., Pinder S.E., Paish C.E., Bell J., Blamey R.W., Roberstson J.F., et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004, 203:661-671.
8. Nishimura R., Arima N. Is triple-negative a prognostic factor in breast cancer. Breast Cancer 2008, 15(4):303-308.
9. Chen X.S., Ma C.D., Wu J.Y., Yang W.T., Lu H.F., Wu J., et al. Molecular subtype approximated by quantitative estrogen receptor, progesterone receptor and Her2 can predict the prognosis of breast cancer. Tumori 2010, 96(1):103-110.
10. Minami Christina A., Chung Debra U., Chang Helena R. Management options in triple-negative breast cancer. Breast Cancer (Auckl) 2011, 5:175-199.
11. Cheang M.C., Voduc D., Bajdik C., Leung S., McKinney S., Chia S.K., et al. Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 2008, 14:1368-1376.
12. Rakha E.A., Elsheikh S.E., Aleskandarany M.A., Habashi H.O., Green A.R., Powe D.G., et al. Triple-negative breast cancer: distinguishing between basal and non-basal subtypes. Clin Cancer Res 2009, 15:2302-2310.
13. Kreike B., van Kouwenhove M., Horlings H., Weigelt B., Peterse H., Bartelink H., et al. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007, 9(5):R65.
14. Perou C.M. Molecular stratification of triple-negative breast cancers. Oncologist 2010, 15(Suppl. 5):39-48.
15. Conforti R., Boulet T., Tomasic G., Taranchon E., Arriagada R., Spielmann M., et al. Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials Ann Oncol 2007, 18:1477-1483.
16. Podo F., Buydens L.M., Degani H., Hilhorst R., Klipp E., Gribbestad I.S., et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010, 4(3):209-229.
17. Tsuda H., Takarabe T., Hasegawa F., Fukutomi T., Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000, 24:197-202.
18. Yin W., Di G., Zhou L., Lu J., Liu G., Wu J., et al. Time-varying pattern of recurrence risk for Chinese breast cancer patients. Breast Cancer Res Treat 2009, 114(3):527-535.
19. Carey L.A., Perou C.M., Livasy C.A., Dressler L.G., Cowan D., Conway K., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
20. Lund M.J., Trivers K.F., Porter P.L., Coates R.J., Leyland-Jones B., Brawley O.W., et al. Race and triple-negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009, 113(2):357-370.
21. Cunningham J.E., Montero A.J., Garrett-Mayer E., Berkel H.J., Ely B. Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 2009, 21:399-409.
22. Trivers K.F., Lund M.J., Porter P.L., Liff J.M., Flagg E.W., Coates R.J., et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009, 20(7):1071-1082.
23. Vona-Davis L., Rose D.P., Hazard H., Howard-McNatt M., Adkins F., Partin J., et al. Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 2008, 17(12):3319-3324.
24. Winkeljohn D.L. Triple-negative breast cancer. Clin J Oncol Nurs 2008, 12:861-863.
25. Phipps A.I., Malone K.E., Porter P.L., Daling J.R., Li C.I. Body size and risk of luminal, HER2 overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer Epidemiol Biomarkers Prev 2008, 17:2078-2086.
26. Gluz O., Liedtke C., Gottschalk N., Pusztai L., Nitz U., Harbeck N. Triple-negative breast cancer - current status and future directions. Ann Oncol 2009, 20:1913-1927.
27. Kallel-Bayoudh I., Ben Hassen H., Khabir A., Boujelbene N., Daoud J., Frikha M., et al. BCL-2 expression and triple-negative profile in breast carcinoma. Med Oncol 2011, 28(Suppl. 1):S55-S61.
28. Kallel I., Khabir A., Boujelbene N., Abdennadher R., Daoud J., Frikha M., et al. EGFR overexpression relates to triple-negative profile and poor prognosis in breast cancer patients in Tunisia. J Recept Signal Transduct Res 2012, 32(3):142-149.
29. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13(15 Pt 1):4429-4434.
30. Tischkowitz M., Brunet J.S., Bégin L.R., Huntsman D.G., Cheang M.C., Akslen L.A., et al. Use of immunohistochemical markers can refine prognosis in triple-negative breast cancer. BMC Cancer 2007, 7:134.
31. Ly M., Antoine M., Dembélé A.K., Levy P., Rodenas A., Touré B.A., et al. High incidence of triple-negative tumors in Sub-Saharan Africa: a prospective study of breast cancer characteristics and risk factors in Malian women seen in a Bamako University Hospital. Oncology 2012, 83(5):257-263.
32. Yao-Lung K., Dar-Ren C., Tsai-Wang C. Clinicopathological features of triple-negative breast cancer in Taiwanese women. Int J Clin Oncol 2011, 16:500-505.
33. Kakarala M., Rozek L., Cote M., Liyanage S., Brenner D.E. Breast cancer histology and receptor status characterization in Asian Indian and women in the USA a SEER analysis. BMC Cancer 2010, 10:191.
34. Ambroise M., Ghosh M., Mallikarjuna V.S., Kurian A. Immunohistochemical profile of breast cancer patients at a tertiary care hospital in South India. Asian Pac J Cancer Prev 2011, 12(3):625-629.
35. Prabhu J.S., Wahi K., Korlimarla A., Correa M., Manjunath S., Raman N., et al. The epigenetic silencing of the estrogen receptor (ER) by hypermethylation of the ESR1 promoter is seen predominantly in triple-negative breast cancers in Indian women. Tumor Biol 2012, 33:315-323.
36. Akasbi Y., Bennis S., Abbass F., Znati K., Joutei K.A., Amarti A., et al. Clinicopathological, therapeutic and prognostic features of the triple-negative tumors in Moroccan breast cancer patients (experience of Hassan II university hospital in Fez). BMB 2011, 4:500.
37. Turkoz F.P., Solak M., Petekkaya I., Keskin O., Kertmen N., Sarici F., et al. Association between common risk factors and molecular subtypes in breast cancer patients. Breast 2012, S0960-9776(12):173-177.
38. Wojcinski S., Soliman A.A., Schmidt J., Makowski L., Degenhardt F., Hillemanns P. Sonographic features of triple-negative and non-triple-negative breast cancer. J Ultrasound Med 2012, 31(10):1531-1541.
39. Skarlos P., Christodoulou C., Kalogeras K.T., Eleftheraki A.G., Bobos M., Batistatou A., et al. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial. Cancer Chemother Pharmacol 2012, 69(2):533-546.
40. Kanapathy Pillai S.K., Tay A., Nair S., Leong C.O. Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin Pathol 2012, 12(1):18.
41. Sioshansi S., Ehdaivand S., Cramer C., Lomme M.M., Price L.L., Wazer D.E. Triple-negative breast cancer is associated with an increased risk of residual invasive carcinoma after lumpectomy. Cancer 2012, 118(16):3893-3898.
42. Agurs-Collins T., Rosenberg L., Makambi K., Palmer J.R., Adams-Campbell L. Dietary patterns and breast cancer risk in women participating in the Black Women's Health Study. Am J Clin Nutr 2009, 90(3):621-628.
43. Turner N., Tutt A., Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004, 4:814-819.
44. Turner N.C., Reis-Filho J.S. Basal-like breast cancer and the BRCA 1 phenotype. Oncogene 2006, 25:5846-5853.
45. Turner N.C., Reis-Filho J.S., Russell A.M., Springall R.J., Ryder K., Steele D., et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 2007, 14:2126-2132.
46. Schneider B.P., Winer E.P., Foulkes W.D., Garber J., Perou C.M., Richardson A., et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14:8010-8018.
47. Cleator S., Heller W., Coombes R.C. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244.
48. Hynes N.E., Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005, 5:341-354.
49. Burgess A.W. EGFR family: structure physiology signalling and therapeutic targets. Growth Factors 2008, 26(5):263-274.
50. Tsutsui S., Ohno S., Murakami S., Hachitanda Y., Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat 2002, 71:67-75.
51. Kurebayashi J., Okubo S., Yamamoto Y., Sonoo H. Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer. Breast Cancer 2004, 11:38-41.
52. Dogu G.G., Ozkan M., Ozturk F., Dikilitas M., Er O., Ozturk A. Triple-negative breast cancer: immunohistochemical correlation with basaloid markers and prognostic value of surviving. Med Oncol 2010, 27:34-39.
53. De Laurentiis M., Cianniello D., Caputo R., Stanzione B., Arpino G., Cinieri S., et al. Treatment of triple-negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev 2010, 36(Suppl. 3):S80-S86.
54. Xie B., Tsao S.W., Wong Y.C. Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgens. Carcinogenesis 1999, 20:1597-1606.
55. Wong Y.C., Xie B. The role of androgens in mammary carcinogenesis. Ital J Anat Embryol 2001, 106:111-125.
56. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., et al. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 1998, 90:1292-1299.
57. Moinfar F., Okcu M., Tsybrovskyy O., Regitnig P., Lax S.F., Weybora W., et al. Androgen receptors frequently are expressed in breast carcinomas. Potential relevance to new therapeutic strategies. Cancer 2003, 98:703-711.
58. Neimeier L.A., Dabbs D.J., Beriwal S., Striebel J.M., Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor - positive tumors and in estrogen receptor - negative tumors with apocrine differentiation. Mod Pathol 2010, 23:205-212.
59. Qi J.P., Yang Y.L., Zhu H., Wang J., Jia Y., Liu N., et al. Expression of the androgen receptor and its correlation with molecular subtypes in 890 Chinese breast cancer patients. Breast Cancer (Auckl) 2012, 6:1-8.
60. Gucalp A., Traina T.A. Triple-negative breast cancer: role of the androgen receptor. Cancer J 2010, 16:62-65.
61. Micello D., Marando A., Sahnane N., Riva C., Capella C., Sessa F. Androgen receptor is frequently expressed in HER2 positive, ER/PR negative breast cancers. Virchows Arch 2010, 457:467-476.
62. Cimino-Mathews A., Hicks J.L., Illei P.B., Halushka M.K., Fetting J.H., De Marzo A.M., et al. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy. Hum Pathol 2012, 43(7):1003-1011.
63. Peters A.A., Buchanan G., Ricciardelli C., Bianco-Miotto T., Centenera M.M., Harris J.M., et al. Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res 2009, 69:6131-6140.
64. Nahleh Z. Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory. Future Oncol 2008, 4:15-21.
65. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 2003, 195:158-167.
66. Callagy G.M., Webber M.J., Pharoah P.D., Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer 2008, 8:153.
67. McDonnell T.J., Korsmeyer S.J. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t (14; 18). Nature 1991, 349:254-256.
68. Pieten pol J.A., Papadopoulos N., Markowitz S., Willson J.K., Kinzler K.W., Vogelstein B. Paradoxical inhibition of solid tumor cell-growth by bcl2. Cancer Res 1994, 54:3714-3717.
69. Van Slooten H.J., Clahsen P.C., van Direndonck J.H., Duval C., Pallud C., Mandard A.M., et al. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy. Br J Cancer 1996, 74:78-85.
70. Lee K.H., Im S.A., Oh D.Y., Lee S.H., Chie E.K., Han W., et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer 2007, 7:63.
71. Nadler Y., Camp R.L., Giltnane J.M., Moeder C., Rimm D.L., Kluger H.M., et al. Expression Patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res 2008, 10:R35.
72. Dawson S.J., Makretsov N., Blows F.M., Driver K.E., Provenzano E., Le Quesne J., et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010, 103(5):668-675.
73. Bhargava V., Kell D.L., Van de Rijn M., Warnke R.A. Bcl-2 immunoreactivity in breast carcinoma correlates with hormone receptor positivity. Am J Pathol 1994, 145:535-540.
74. Kolacinska A., Chalubinska J., Zawlik I., Szymanska B., Borowska-Garganisz E., Nowik M., et al. Apoptosis-, proliferation, immune function-, and drug resistance-related genes in ER positive, HER2 positive and triple-negative breast cancer. Neoplasma 2012, 59(4):424-432.
75. Tawfik K., Kimler B.F., Davis M.K., Fan F., Tawfik O. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors. Hum Pathol 2012, 43(1):23-30.
76. Afify A., Purnell P., Nguyen L. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion. Exp Mol Pathol 2009, 86:95-100.
77. Klingbeil P., Natrajan R., Everitt G., Vatcheva R., Marchio C., Palacios J., et al. CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Res Treat 2010, 120:95-109.
78. Bauerschmitz G.J., Ranki T., Kangasniemi L., Ribacka C., Eriksson M., Porten M., et al. Tissue specific promoters active in CD44? CD24-/low breast cancer cells. Cancer Res 2008, 68:5533-5539.
79. Hough M., Rosten P.M., Sexton T.L., Kay R., Humphries R.K. Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics 1994, 22:154-161.
80. Lim S.C. CD24 and human carcinoma: tumor biological aspects. Biomed Pharmacother 2005, 59(Suppl. 2):S351-S354.
81. Idowu M.O., Kmieciak M., Dumur C., Burton R.S., Grimes M.M., Powers C.N., et al. CD44+/CD24-/low cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 2012, 43(3):364-373.
82. Reuben J.M., Lee B.N., Gao H., Cohen E.N., Mego M., Giordano A., et al. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44(+)CD24(lo) cancer stem cell phenotype. Eur J Cancer 2011, 47:1527-1536.
83. Liu S., Ginestier C., Charafe-Jauffret E., Foco H., Kleer C.G., Merajver S.D., et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A 2008, 105(5):1680-1685.
84. Wooster R., Weber B.L. Breast and ovarian cancer. N Engl J Med 2003, 348(23):2339-2347.
85. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134.
86. Robson M., Offit K. Management of an inherited predisposition to breast cancer. N Engl J Med 2007, 357:154-162.
87. Stoppa-Lyonnet D., Ansquer Y., Dreyfus H., Gautier C., Gauthier-Villars M., Bourstyn E., et al. Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol 2000, 18:4053-4059.
88. Kurebayashi J. Possible treatment strategies for triple-negative breast cancer on the basis of molecular characteristics. Breast Cancer 2009, 16(4):275-280.
89. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple-negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
90. Comen E., Davids M., Kirchhoff T., Hudis C., Offit K., Robson M. Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. Breast Cancer Res Treat 2011, 129(1):185-190.
91. Hollstein M., Sidransky D., Vogelstein B., Harris C.C. p53 mutations in human cancers. Science 1991, 253(5015):49-53.
92. Liu Y.Y., Patwardhan G., Bhinge K., Gupta V., Gu X., Jazwinski M. Suppression of glucosylceramide synthase restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer Res 2011, 71(6):2276-2285.
93. Braicu C., Pileczki V., Irimie A., Berindan-Neagoe I. p53siRNA therapy reduces cell proliferation, migration and induces apoptosis in triple-negative breast cancer cells. Mol Cell Biochem 2013, 381:61-68.
94. Sørlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98(19):10869-10874.
95. Troester M.A., Herschkowitz J.I., Oh D.S., He X., Hoadley K.A., Barbier C.S., et al. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer 2006, 6:276.
96. Hui R., Macmillan R.D., Kenny F.S., Musgrove E.A., Blamey R.W., Nicholson R.I., et al. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Clin Cancer Res 2000, 6:2777-2787.
97. Milde-Langosch K., Bamberger A.M., Rieck G., Kelp B., Löning T. Overexpression of the p16 cell cycle inhibitor in breast cancer is associated with amore malignant phenotype. Breast Cancer Res Treat 2001, 67:61-70.
98. Karray-Chouayekh S., Baccouche S., Khabir A., Sellami-Boudawara T., Daoud J., Frikha M., et al. Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma. Acta Histochemica 2011, 113(5):508-513.
99. Kuroda N., Ohara M., Inoue K., Mizuno K., Fujishima N., Hamaguchi N., et al. The majority of triple-negative breast cancer may correspond to basal-like carcinoma, but triple-negative breast cancer is not identical to basal-like carcinoma. Med Mol Morphol 2009, 42:128-131.
100. Kim S., Jung H.W., Koo J.S. Differences in autophagy-related activity by molecular subtype in triple-negative breast cancer. Tumor Biol 2012, 33:1681-1694.